Company intelligence / Profile preview

Aramis Therapeutics

Medfield, Massachusetts, United States

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Aramis Biosciences has completed enrollment of its Phase II clinical trial evaluating A197, a novel, first-in-class topical immunomodulatory agent, for the treatment of dry eye disease, with proof-of-concept data anticipated by Q1 2023[5].

Therapeutic areas: ImmunologyOphthalmology
Modalities: Small moleculeImmunomodulatory agent
Industry: Biotech

Partnerships

Safar PartnersDompé farmaceutici S.p.A.Global leader in ophthalmic pharmaceuticals (likely Santen, per Scientific Advisory Board)

Beyond the preview

Go deeper on Aramis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aramis Therapeutics.

Explore the full profile